SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a massive, unsolicited $56 billion bid to acquire eBay, a move that has ignited intense debate over potential stock dilution versus the strategic ambition to build an e-commerce rival to Amazon. The community remains deeply polarized, with bulls viewing the play as a bold, long-term transformational move, while vocal bears and skeptics are heavily criticizing the CEO's confrontational media presence and the logistical hurdles of the proposed financing.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing extreme volatility driven by a prospectus filing that registers a large volume of existing Class B shares for potential resale, which the community is debating as either a standard liquidity event or a sign of an impending supply overhang. Investors are actively discussing the technical merits of the company's photonic quantum approach, while many express mixed sentiment over the stock's speculative nature and the rapid price fluctuations following the registration news.

Elong Power Holding Ltd. engages in the research and development, manufacturing, sales and service of high-power lithium-ion batteries for electric vehicles and construction machinery, as well as large-capacity, long-cycle lithium-ion batteries for energy storage systems. The company was founded on August 18, 2023 and is headquartered in Ganzhou, China.

Elong Power Holding Ltd. - Ordinary Shares - Class A

Elong Power Holding Limited

Elong Power Holding Limited (ELPW) is experiencing high-volume volatility and active short-squeeze speculation, with the community closely tracking the ticker alongside other low-float, China-based small caps. Retail traders are intensely focused on key price levels and resistance breakouts while debating the sustainability of the move versus potential downside risk.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing intense investor interest driven by a massive short squeeze setup, characterized by high borrowing costs and low share availability. The community is focused on the upcoming earnings report as a major catalyst for momentum, with many bulls actively discouraging selling and urging a long-term hold to maximize pressure on short sellers.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively buy into a structural memory supercycle, with community members highlighting that AI infrastructure demand for DRAM and HBM is decoupling the stock from traditional cyclical patterns. Bullish sentiment remains dominant as market participants point to supply shortages and major hyperscale partnerships as the primary drivers, with many actively discussing the potential for a massive rerating as the stock approaches new highs.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently a focal point for investors as the community anticipates critical upcoming data regarding biomarker analysis and potential FDA accelerated approval pathways for its ALS candidate, CNM-Au8. Discussion is heavily focused on the company's regulatory roadmap, the impact of recent insider selling, and the broader context of how emerging biomarker evidence could influence the stock's long-term valuation.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals is experiencing intense volatility and volume as investors react to a private placement financing announcement, fueling intense community debates about potential squeezes versus long-term dilution concerns. Retail traders are closely monitoring the stock's tight float and rapid price swings, with active discussions centered on technical breakout levels and the company's shifting strategic focus.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following an unsolicited takeover proposal from GameStop, which has fueled intense community debate over the feasibility of the deal and the potential for a massive acquisition strategy. Market participants are actively scrutinizing the financing requirements and the viability of a cash-and-stock offer that significantly exceeds GameStop's current market valuation.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is generating significant discussion as investors weigh the company's Q1 2026 earnings beat and full-year guidance against the ongoing challenges of rising fuel costs, union labor contracts, and a strategic pivot away from low-margin Amazon volume. While some in the community see the aggressive restructuring and automation efforts as a long-term turnaround play, others remain highly skeptical, pointing to declining parcel volumes and competitive pressure from FedEx as reasons to avoid the stock.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing significant volatility as market participants monitor legislative developments surrounding the Clarity Act, with the community actively debating the potential impact of new stablecoin yield and rewards regulations. Investors are closely tracking how these regulatory shifts could influence future payment infrastructure growth while managing exposure amidst ongoing debates over the stock's long-term valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CNS Pharmaceuticals plans to use the proceeds, along with existing cash, to identify and acquire new drug candidates in neurology and oncology.</li><li>The company is looking to out-license its legacy programs, including Berubicin and TPI-287, to treat tumors.</li><li>The biotech firm will look to acquire or license preclinical and clinical-stage assets with clear development paths and strong commercial potential.</li></ul>Shares of CNS Pharmaceuticals Inc. (CNSP) rocketed over 330% in early trade on Monday, registering their biggest ever single-day gains since implementing a 1-for-12 reverse stock split last July, as investors cheered a $22.5 million private placement to boost its acquisition strategy.The financing includes participation from institutional healthcare investors such as ADAR1 Capital, Ikarian Capital, Stonepine Capital Management, and Nazare Partners.The private placement involves the sale of 650,000 common shares at $2.30 each, along with pre-funded warrants tied to over 9.1 million shares. CNSP shares closed at $2.31 on Friday.“With the proceeds from this financing, the company is now in a strong position to execute on our recently announced corporate strategy and capitalize on opportunities created by the dynamic biotech environment over the last several years,” said Rami Levin, President and CEO of CNS Pharmaceuticals.<h2 class="st-heading-2">Strategic Shift Toward Acquisitions, Licensing</h2>CNS Pharmaceuticals plans to use the proceeds, along with existing cash, to identify and acquire new drug candidates in neurology and oncology. The company is prioritizing assets with clear development paths, strong scientific backing, and near-term catalysts.At the same time, the firm is looking to out-license its legacy programs, including Berubicin and TPI-287, to treat tumors.In March, CNS Pharmaceuticals <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cnspharma.com/cns-pharmaceuticals-launches-new-corporate-strategy-focused-on-building-a-high-value-neurology-and-oncology-pipeline/">announced</a> a new growth strategy focused on building a strong pipeline in neurology and oncology. The biotech firm will look to acquire or license preclinical and clinical-stage assets, prioritizing programs with clear development paths and strong commercial potential.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CNSP">CNSP</a> on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user saw $11 to $12 as a key resistance level.<stembedurl>https://stocktwits.com/cjstocksup/message/652162741</stembedurl>However, another user expects the stock to drop “hard.”<stembedurl>https://stocktwits.com/belikemike7/message/652165417</stembedurl>The stock is up 70% year-to-date.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-xndu-stock-down-today-xanadu-quantum-share-registration/cZQMsDAReJ4">XNDU Stock Crashed 68%, But It’s Not A New Offering – Retail Traders Call It An ‘Overreaction’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Why Did CNSP Stock Surge 330% Today?

The company announced a private placement, involving the sale of 650,000 common shares at $2.30 each, along with pre-funded warrants tied to over 9.1 million shares.

Equity

Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

CNS Pharmaceuticals announces $22.5 million financing as the company pivots its strategy, eyes asset acquisitions.read more...

CNS Pharmaceuticals Secures $22.5 M in Oversubscribed Private Placement

CNS Pharmaceuticals (NASDAQ:CNSP) significantly boosted its capital reserves, entering into securities purchase agreements for a private placement expected to generate $22.5 million in gross proceeds.

Shares of CNS Pharmaceuticals, Inc. (CNSP) declined 5% on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-announces-primary-analysis-of-berubicin-in-second-line-treatment-of-glioblastoma-multiforme-44471506">reported </a>wider losses in the first quarter (Q1).The firm’s net loss for the three months ended March 31, 2025, was approximately $4.3 million, compared to approximately $3.5 million for the comparable period in 2024.The company said the increase in net loss is largely attributable to the costs of data clean-up, preparation, and analysis for the topline primary data release on the Berubicin trial in brain cancer.CNS Pharmaceuticals’ research and development expenses rose to $3.2 million in the quarter, while general and administrative expenses fell marginally to $1.09 million, owing to a decrease in stock-based compensation, marketing, advertising, and insurance expenses.The company ended the quarter with cash of approximately $13.1 million. CNS believes that the cash on hand as of March 31, 2025, in addition to the $5 million raised from a public offering earlier this month, is sufficient to fund planned operations into the second half of 2026.CNS is developing treatments for cancers in the brain and central nervous system. By year-end, the company intends to commence the phase 2 study of its lead program, TPI 287, for treating Glioblastoma Multiforme (GBM). Glioblastoma multiforme (GBM) is the most common form of cancer that originates in the brain.On Stocktwits, retail sentiment around CNSP remained ‘extremely bullish’ over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_9_01_42_AM_png_cf9bcf9c43.webp" alt="CNSP's Sentiment Meter and Message Volume as of 9 a.m. ET on May 16, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>CNSP's Sentiment Meter and Message Volume as of 9 a.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CNSP">CNSP stock</a> is down by 80% this year and over 99% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-ceo-to-step-down/chiw5m5Rbno">Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved

The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.

This account has been verified as an official CNSP representative.

Verified Account

CNS Pharma

Continue higher

Sideways action

Retreat lower

What’s your read on the market for next week?

Stocktwits

Stocktwits Polls

Traders are reacting to an oversubscribed $22.5M private placement that triggered extreme volatility and massive volume spikes.

The stock's low-float nature is fueling aggressive short-covering rallies and parabolic momentum moves that attract intense intraday speculation.

Concerns remain high regarding the impact of warrants priced at $2.31, leading to debates about long-term valuation versus speculative gains.

CNSP
Cns Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CNSP News

CNSPCns Pharmaceuticals Inc